Background
- End-stage hepatic fibrosis with hepatic dysfunction
Epidemiology
- 25% of Canadians have NAFLD
Etiology
- Infectious
- Toxins and drugs
- Autoimmune/inflammatory
- Metabolic
- Other
JAMA Rational Clinical Exam
- Ascites (LR+ 7.2)
- Platelet count <160 (LR+ 6.3; LR- 0.29 if ≥160)
- Spider nevi (LR+ 4.3)
- Bonacini cirrhosis discriminant score >7 (LR+ 9.4)
- Lok index <0.2 (LR- 0.09)
- Absence of hepatomegaly (LR- 0.37)
Investigations
- Lab abnormalities in liver failure, in order:
- Decrease in platelets
- Increase in bilirubin
- Decrease in albumin
- Increase in INR
- Investigations for possible causes of cirrhosis include:
- Liver ultrasound
- Hepatitis B and C serologies
- Ferritin and transferrin saturation, for hereditary hemochromatosis
- Autoimmune serologies
- ANA and anti-smooth muscle antibodies, for PSC and AIH
- Anti-mitochondrial antibodies and anti-parietal cell antibodies, for PBC
- Consider anti-LKM-1, for PSC
- Quantitative immunoglobulins, for elevated IgM in PBC or hypergammaglobulinemia in AIH
- Consider serum ceruloplasmin, for Wilson disease
- Consider α-1 antitripsyin levels, for deficiency
Management
- Decompensated
- Ascites
- Furosemide 40 and spironolactone 100 (max 160/400)
- Serial therapeutic paracentesis
- Small-volume (<4-5L) does not need albumin
- Large-volume needs 6-8 g of 25% albumin per litre removed
- Avoid indwelling drain
- TIPS can be considered but precipitates encephalopathy
- Prophylaxis/chronic
- SBP: maybe?
- Encephalopathy: no role for primary prophylaxis
- Surveillance with upper endoscopy
- Ultrasound q6mo for HCC
Preventative Care
- Avoid raw oysters (high risk of Vibrio vulnificans infection in cirrhosis)
Prognosis
- Median survival 1.6 years after admission for decompensated cirrhosis